Kaposi Sarcoma Incidence in Swiss HIV Cohort Study
Author Information
Author(s): Franceschi S, Maso L Dal, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S, Jundt G, Mueller N, Clifford G M
Primary Institution: International Agency for Research on Cancer
Hypothesis
What are the changes in Kaposi sarcoma incidence before and after the introduction of highly active antiretroviral therapy (HAART)?
Conclusion
The incidence of Kaposi sarcoma significantly decreased after the introduction of HAART among people with HIV/AIDS.
Supporting Evidence
- Kaposi sarcoma incidence fell abruptly in 1996–1998.
- Among HAART users, KS incidence decreased from 15.0 to 1.3 per 1000 person-years.
- 63.5% of KS cases among HAART users arose from those who had stopped treatment or used HAART for less than 6 months.
Takeaway
This study shows that after starting a special treatment for HIV, the number of people getting a type of cancer called Kaposi sarcoma went down a lot.
Methodology
The study analyzed data from the Swiss HIV Cohort Study, including 12,959 participants, to assess Kaposi sarcoma incidence and risk factors before and after HAART.
Potential Biases
The evaluation of HAART use was by intention-to-treat, which may underestimate its efficacy.
Limitations
The study lacked information on the year of HIV seroconversion and the presence of KS herpesvirus co-infection.
Participant Demographics
Participants included individuals with HIV/AIDS, primarily from Switzerland, with a significant proportion being men who have sex with men.
Statistical Information
P-Value
0.06
Confidence Interval
95% CI, 0.02–0.17
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website